Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 4/20 | 0.60 |
| ▸ | MMP9 | P14780 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MMP1 | P03956 | 1/20 | 0.60 |
| ▸ | MMP3 | P08254 | 1/20 | 0.60 |
| ▸ | MMP7 | P09237 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138984 | 1.00 | KDM4E (0.61) | KDM4ELARS1MMP2MMP9MEN1 | |
| SCHEMBL15251693 | 1.00 | KDM4E (0.61) | KDM4ELARS1MMP2MMP9MEN1 | |
| SCHEMBL7948476 | 0.88 | LARS1 (0.62) | KDM4ELARS1MMP2MMP9MMP1 | |
| SCHEMBL1770896 | 0.88 | LARS1 (0.62) | KDM4ELARS1MMP2MMP9MMP1 | |
| SCHEMBL1770524 | 0.87 | LARS1 (0.58) | KDM4ELARS1CYP2C9SLC1A3SLC1A2 | |
| SCHEMBL1770779 | 0.87 | LARS1 (0.58) | KDM4ELARS1CYP2C9SLC1A3SLC1A2 | |
| SCHEMBL30919401 | 0.86 | SLC1A3 (0.60) | KDM4ELARS1MMP2MMP9CYP2C9 | |
| SCHEMBL15731854 | 0.86 | SLC1A3 (0.60) | KDM4ELARS1MMP2MMP9CYP2C9 | |
| SCHEMBL15708513 | 0.86 | SLC1A3 (0.60) | KDM4ELARS1MMP2MMP9CYP2C9 | |
| SCHEMBL6434896 | 0.85 | SLC1A3 (0.61) | MMP2MMP9MMP13SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1992016549-A1 | PARASUBSTITUTED PHENYLALANINE DERIVATES | PENTAPHARM AG (CH) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885LARS1 4624/4885MMP2 24/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | KDM4E 875/4885LARS1 3931/4885MMP2 37/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885LARS1 4624/4885MMP2 24/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885LARS1 4624/4885MMP2 24/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KDM4E 917/4885LARS1 4624/4885MMP2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.